​President and CEO, Recros Medica

Thomas Albright

Long-time medical aesthetic executive whose experience includes leadership of some of the most innovative brands in the sector.

Mr. Albright has 37 years experience in pharmaceutical, biologic, device and aesthetic-related sales, marketing and general management roles. Mr. Albright joined Recros in April 2017 and is currently President and CEO. Since 2011, he had been Chairman and CEO of Andrew Technologies LLC, an aesthetic surgical device company.

Mr. Albright was also on the Board of Directors of Bonti from 2016 to its acquisition by Allergan in 2018. From 2010 to 2011, he was president of the topical aesthetic division at Syneron Medical Ltd, a global medical aesthetic device company. From 2008 to 2010, Mr. Albright was VP of North American marketing at Nobel Biocare, a leading dental aesthetics company. His medical aesthetic experience commenced with Allergan (2000 – 2008), where he led the launch of BOTOX® Cosmetic and the commercial development of Latisse®. At Allergan, Mr. Albright was also the alliance manager for the strategic collaboration with GlaxoSmithKline in China, Japan, and the US. In 1983, he commenced his career in healthcare with the Parke-Davis division of Warner Lambert, where he held sales and marketing leadership roles, including the 1997 launch of Lipitor®, among other brands.

Prior to beginning his healthcare career, Mr. Albright was an officer in the US Air Force. He has a BS in biology from The Citadel and an MBA in marketing from Mercer University.

Let's continue the conversation

Contact us for more information about eon by completing this form or directly at 800-979-6801 or email info@dominionaesthetic.com.

Copyright © 2020 Dominion Aesthetic Technologies, Inc. All rights reserved. This material also contains registered trademarks, trade-names and brand names of Dominion Aesthetic Technologies, Inc. and no right or license to use such names and marks is granted.